The Wales site provides chemical development services and small- and large scale-manufacturing services of APIs (active pharmaceutical ingredients) and intermediates. AMRI initially considered selling the site but it seems that plan did not materialize.
The site’s closure was first announced in February as efforts to use the site as a conduit between the company’s European and US operations proved unsuccessful. Since 2012, the company has closed sites in Washington state, Hungary and Albany, NY. However, the company still has an aseptic manufacturing site in Glasgow, UK, which AMRI acquired earlier this year, and most recently, the company said it has its sights set on an Indian API manufacturer.
AMRI will transition activities at the Holywell site to other facilities within the AMRI network and plans to cease operations at the site by the end of 2015.
William Marth, AMRI President and CEO, said: "We will work diligently to ensure the closing of the Holywell facility goes as smoothly as possible for our customers and employees."